Devonian Health Group (DVHGF) Stock Overview

Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, the company acquires drug and health product licenses; and distributes pharmaceutical products. Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec, Canada.

DVHGF Stock Information

Symbol

DVHGF

Address

360, rue des EntrepreneursQuébec, QC G5V 4T1Canada

Founded

Trading hours

Website

https://groupedevonian.com

Country

🇨🇦 Canada

Phone Number

514 248 7509

Devonian Health Group (DVHGF) Price Chart

Devonian Health Group Overview: Key Details and Summary

Stock data	2023	Change
Price	$0.16	N/A
Market Cap	$21.69M	N/A
Shares Outstanding	135.57M	13.89%
Employees	6.00	N/A
Shareholder Equity	14.25M	-12.44%

Valuation	2023	Change
P/E Ratio	-4.71	N/A
P/S Ratio	12.59	N/A
P/B Ratio	1.52	N/A

Growth	2023	Change
Return on Equity	-0.2371	N/A

Earnings	2023	Change
Revenue	$1.72M	N/A
Earnings	-$3.38M	N/A
EPS	-0.034	N/A
Earnings Yield	-0.2125	N/A
Gross Margin	0.3805	N/A
Operating Margin	-1.84	N/A
Net income margin	-1.96	N/A

Financial Strength	2023	Change
Total Assets	$14.09M	N/A
Total Debt	$2.70M	N/A
Cash on Hand	$3.72M	N/A
Debt to Equity	0.2542	5.97%
Cash to Debt	$1.38	-24.47%
Current Ratio	$1.31	-73.29%